Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia

被引：0

作者：

Wendtner, Clemens M. ^{[1
]}

Mahadevan, Daruka ^{[2
]}

Stilgenbauer, Stephan ^{[3
]}

Frankfurt, Olga ^{[4
]}

Bloor, Adrian ^{[5
]}

Bosch, Francesc ^{[6
]}

Uharek, Lutz ^{[7
]}

Furman, Richard R. ^{[8
]}

Gobbi, Marco ^{[9
]}

Gribben, John G. ^{[10
]}

Kimby, Eva K. ^{[11
]}

Sekeres, Mikkael A. ^{[12
]}

Cripe, Larry D. ^{[13
]}

Lombardy, Elyane ^{[14
]}

Shah, Sheetal ^{[14
]}

Moutouh-de Parseval, Laure A. ^{[14
]}

Chanan-Khan, Asher Alban ^{[15
]}

Knight, Robert D. ^{[14
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[2] Arizona Canc Ctr, Tucson, AZ USA

[3] Univ Ulm, Ulm, Germany

[4] NW Mem Hosp, Robert H Lurie CCC, Chicago, IL 60611 USA

[5] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[6] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[7] Charite Univ Med Berlin, Med Clin Hematol Oncol 3, Berlin, Germany

[8] Weill Cornell Med Coll, Dept Hematol Oncol, New York, NY USA

[9] Univ Genova Italy, Genoa, Italy

[10] Barts & London Queen Marys Sch Med & Dent, London, England

[11] Karolinska Inst, Hematol Ctr, Stockholm, Sweden

[12] Cleveland Clin, Cleveland, OH 44106 USA

[13] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[14] Celgene Corp, Summit, NJ USA

[15] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：732 / 732

页数：1

共 50 条

[1] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
Wendtner, Clemens
Hillmen, Peter
Mahadevan, Daruka
Stilgenbauer, Stephan
Uharek, Lutz
Coutre, Steven
Frankfurt, Olga
Bloor, Adrian
Bosch, Francesc
Furman, Richard R.
Kimby, Eva
Gribben, John G.
Gobbi, Marco
Dreisbach, Luke
Hurd, David Duane
Sekeres, Mikkael A.
Ferrajoli, Alessandra
Shah, Sheetal
Zhang, Jennie
de Parseval, Laure Moutouh
Chanan-Khan, Asher A.
[J]. BLOOD, 2010, 116 (21) : 591 - 592
[2] A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.
Camacho, Luis H.
Joyce, Robin
Brown, Jennifer R.
Chanan-Khan, Asher
Amrein, Philip C.
Assad, Albert
Carrigan, Marion
[J]. BLOOD, 2009, 114 (22) : 1330 - 1330
[3] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
Huetter, Marie-Luise
Fiedler, Walter
Kuendgen, Andrea
Krauter, Juergen
von Lilienfeld-Toal, Marie
Kayser, Sabine
Rafler, Heidi
Doehner, Hartmut
Schlenk, Richard F.
[J]. BLOOD, 2010, 116 (21) : 1350 - 1351
[4] Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study
Xu, Wei
Zhou, Keshu
Wang, Tingyu
Yang, Shenmiao
Liu, Lihong
Hu, Yu
Zhang, Wei
Ding, Kaiyang
Zhou, Jianfeng
Gao, Sujun
Xu, Bing
Zhu, Zunmin
Liu, Ting
Zhang, Huilai
Hu, Jianda
Ji, Chunyan
Wang, Shunqing
Xia, Zhongjun
Wang, Xin
Li, Yan
Song, Yongping
Ma, Shuo
Tang, Xinran
Zhang, Bin
Li, Jianyong
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (04) : 571 - 579
[5] A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
Lubner, Sam Joseph
Mullvain, Jacqueline
Perlman, Scott
Pishvaian, Michael
Mortimer, Joanne
Oliver, Katherine
Heideman, Jennifer
Hall, Lance
Weichert, Jamey
Liu, Glenn
[J]. CANCER INVESTIGATION, 2015, 33 (10) : 483 - 489
[6] ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study
Naoe, Tomoki
Sakura, Toru
Kobayashi, Yukio
Usuki, Kensuke
Miyamoto, Toshihiro
Iida, Hiroatsu
Morita, Satoshi
Bahceci, Erkut
Kaneko, Masahito
Yamada, Shunsuke
Takeshita, Shigeru
Miyawaki, Shuichi
[J]. BLOOD, 2015, 126 (23)
[7] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
Zwaan, C. Michel
Soderhall, Stefan
Brethon, Benoit
Luciani, Matteo
Rizzari, Carmelo
Stam, Ronald W.
Besse, Emmanuelle
Dutreix, Catherine
Fagioli, Franca
Ho, Phoenix A.
Dufour, Carlo
Pieters, Rob
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
[8] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Bagshaw, Meghan
Schlossman, Robert
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Laubach, Jacob
Jakubowiak, Andrzej J.
Maiso, Patricia
Roccaro, Aldo
Armand, Philippe
Dollard, Akari
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott
Anderson, Kenneth C.
Richardson, Paul G.
[J]. LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
[9] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
Dunn, Tamara J.
Dinner, Shira
Price, Elizabeth
Coutre, Steven E.
Gotlib, Jason
Hao, Ying
Berube, Caroline
Medeiros, Bruno C.
Liedtke, Michaela
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
[10] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Hamadani, Mehdi
Collins, Graham P.
Caimi, Paolo F.
Samaniego, Felipe
Spira, Alexander
Davies, Andrew
Radford, John
Menne, Tobias
Karnad, Anand
Zain, Jasmine M.
Fields, Paul
Havenith, Karin
Cruz, Hans G.
He, Shui
Boni, Joseph
Feingold, Jay
Wuerthner, Jens
Horwitz, Steven
[J]. LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445

← 1 2 3 4 5 →